Neuroprotective effect of CGS 26303, an endothelin-converting enzyme inhibitor, on transient middle cerebral artery occlusion in rats

Journal of Cardiovascular Pharmacology

Volumn 44, Issue SUPPL. 1, 2004, Pages

  Chang, Chih Zen ^a   Yen, Chin Po ^a   Winadi, Daniel ^a   Wu, Shu Chuan ^a   Howng, Sheng Long ^a   Lin, Tze Kan ^b   Jeng, Arco Y ^c   Kassell, Neal F ^d   Kwan, Aij Lie ^a,d  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b Department of Neurosurgery   (Taiwan)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Brain blood barrier; CGS 26303; Endothelin converting enzyme inhibitor; Infarction reperfusion; Triple vessel occlusion

Indexed keywords

2 (4 BIPHENYLYL) 1 (1H TETRAZOL 5 YL)ETHYLAMINOMETHYLPHOSPHONIC ACID; ENDOTHELIN CONVERTING ENZYME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN EDEMA; BRAIN INFARCTION SIZE; BRAIN PERFUSION; COMMON CAROTID ARTERY; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NERVOUS SYSTEM INJURY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ASPARTIC ENDOPEPTIDASES; BEHAVIOR, ANIMAL; BRAIN; BRAIN EDEMA; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; INFARCTION, MIDDLE CEREBRAL ARTERY; INJECTIONS, INTRAVENOUS; MALE; METALLOENDOPEPTIDASES; NEUROPROTECTIVE AGENTS; PHOSPHONIC ACIDS; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; TETRAZOLES;

EID: 11144283266     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000166307.86678.d1     Document Type: Conference Paper

References (6)

1. Hiramatsu K, Kassell NF, Goto Y, et al. A preproducible model of reversible, focal, neocortical ischemia in Sprague-Dawley rat. Acta Neumchir (Wien). 1993;120:66-71.
2. Chang CZ, Winardi D, Loh JK, et al. Alteration of ischemic reperfusion injury in the rat neocortex by a potent antioxidant mexiletine. Acta Neurochir (Wien). 2002;144:189-193.
3. Patel TR. Therapeutic potential of endothelin receptor antagonists in cerebrovascular disease. CNS Drugs. 1996;5:293-310.
4. Jeng AY, Mulder P, Kwan A-L, et al. Non-peptidic endothelin converting enzyme inhibitor and their potential therapeutic applications. Can J Physiol Pharmacol. 2002;80:440-449.
5. Bederson JB, Pitts LH, Tsuji M, et al. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17:472-476.
6. De Ryck M, Van Reempts J, Borgers M, et al. Photochemical stroke model: flunarizine prevents sensorimotor deficits after neocortical infarcts in rats. Stroke. 1989;20:1383-1390.